CoChat

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index; 46 of the 79 sources its claims cite were checked for support.

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

Open access

Abstract

Ample evidence indicates that the gut microbiome is a tumor-extrinsic factor associated with antitumor response to anti-programmed cell death protein-1 (PD-1) therapy, but inconsistencies exist between published microbial signatures associated with clinical outcomes. To resolve this, we evaluated a new melanoma cohort, along with four published datasets. Time-to-event analysis showed that baseline microbiota composition was optimally associated with clinical outcome at approximately 1 year after initiation of treatment. Meta-analysis and other bioinformatic analyses of the combined data show that bacteria associated with favorable response are confined within the Actinobacteria phylum and the Lachnospiraceae/Ruminococcaceae families of Firmicutes. Conversely, Gram-negative bacteria were associated with an inflammatory host intestinal gene signature, increased blood neutrophil-to-lymphocyte ratio, and unfavorable outcome. Two microbial signatures, enriched for Lachnospiraceae spp. and Streptococcaceae spp., were associated with favorable and unfavorable clinical response, respectively, and with distinct immune-related adverse effects. Despite between-cohort heterogeneity, optimized all-minus-one supervised learning algorithms trained on batch-corrected microbiome data consistently predicted outcomes to programmed cell death protein-1 therapy in all cohorts. Gut microbial communities (microbiotypes) with nonuniform geographical distribution were associated with favorable and unfavorable outcomes, contributing to discrepancies between cohorts. Our findings shed new light on the complex interaction between the gut microbiome and response to cancer immunotherapy, providing a roadmap for future studies.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01698-2

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

16 Valid · 3 Not valid · 12 Not checked · 109 Own results and interpretations

90 more claims · 11 with their cited sources checked

Create a free account to see all 140 claims and to verify the 33 references still open.

See all claims — free account
  • Probably not a substantial claim. 11
  • It may state two separate claims as one. 37
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

28 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 81 references

Cited by

See all 476

Metadata

Authors
McCulloch, J. A., Davar, D., Rodrigues, R. R., Badger, J. H., Fang, J. R., Cole, A. M., Balaji, A. K., Vetizou, M., Prescott, S. M., Fernandes, M. R., Costa, R. G. F., Yuan, W., Salcedo, R., Bahadiroglu, E., Roy, S., DeBlasio, R. N., Morrison, R. M., Chauvin, J.-M., Ding, Q., Zidi, B., Lowin, A., Chakka, S., Gao, W., Pagliano, O., Ernst, S. J., Rose, A., Newman, N. K., Morgun, A., Zarour, H. M., Trinchieri, G., & Dzutsev, A. K.
Affiliations
  • National Cancer Institute (US)
  • University of Pittsburgh (US)
  • Frederick National Laboratory for Cancer Research (US)
  • Oregon State University (US)
Corresponding author
  • Zarour, Hassane M.
  • Trinchieri, Giorgio
  • Dzutsev, Amiran K.
Venue
Nature Medicine
Published
2022-02-28
Volume
28
Issue
3
Pages
545-556
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4214737502
Cited by
472
References
81
Citations by year
2026: 102 · 2025: 119 · 2024: 104 · 2023: 97 · 2022: 49
FWCI
39.03
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Melanoma Research Foundation (Melanoma Breakthrough Foundation Breakthrough Consortium 2020)
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA257265, P50 CA254865, R01 CA228181, R01 CA222203, P50 CA254865))
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
Keywords
gut microbiota, melanoma, anti-PD-1 therapy, immune checkpoint inhibitors, cancer immunotherapy response, immune-related adverse events, Lachnospiraceae, Ruminococcaceae, Streptococcaceae, actinobacteria, Gram-negative bacteria, neutrophil-to-lymphocyte ratio, microbial signatures, outcome prediction
MeSH terms
Gastrointestinal Microbiome, Bacteria, Humans, Immunotherapy, Melanoma, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. https://app.cochat.ai/papers/10.1038/s41591-022-01698-2
The paper
McCulloch, J. A., Davar, D., Rodrigues, R. R., Badger, J. H., Fang, J. R., Cole, A. M., Balaji, A. K., Vetizou, M., Prescott, S. M., Fernandes, M. R., Costa, R. G. F., Yuan, W., Salcedo, R., Bahadiroglu, E., Roy, S., DeBlasio, R. N., Morrison, R. M., Chauvin, J.-M., Ding, Q., . . . Dzutsev, A. K. (2022). Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nature Medicine. https://doi.org/10.1038/s41591-022-01698-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.